​

Funding Round

Series C - Prellis Biologics

Series C - Prellis Biologics

Investment Firm

Overview

Prellis employs holographic tissue printing technology with fully human antibody discovery, in vitro human disease and ADME/Tox models.

Announced Date

Nov 17, 2023

Funding Type

Series C

Highlights

N/A

Location

N/A

Social

N/A

Investor Lead

N/A

Participant Investors

2

Investor Name
Participant InvestorIndieBio
Participant InvestorSOSV

Round Details and Background

Prellis Biologics raised an undisclosed amount on 2023-11-17 in Series C

Prellis employs holographic tissue printing technology with fully human antibody discovery, in vitro human disease and ADME/Tox models.

Company Funding History

11

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Dec 15, 2021
Series B - Prellis Biologics
2-14.5M
Nov 17, 2023
Series C - Prellis Biologics
2-undefined
Apr 19, 2017
Seed Round - Prellis Biologics
2-120.0K
Sep 13, 2017
Seed Round - Prellis Biologics
4-1.8M

Recent Activity

There is no recent news or activity for this profile.